Erytech Pharma S.A.

General Information
Business:

We are a biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting both solid and liquid tumors for patients with high unmet medical needs. Our lead product candidate, which we refer to as eryaspase or GRASPA, targets the metabolism of cancers by depriving tumor cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells’ rapid growth rate.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 92
Founded: 2004
Contact Information
Address Bâtiment Adénine, 60 Avenue Rockefeller, 69008 Lyon, France
Phone Number +33 4 78 74 44 38
Web Address http://www.erytech.com
View Prospectus: Erytech Pharma S.A.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-30.1 mil (last 12 months)
IPO Profile
Symbol ERYP
Exchange NYSE
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Jefferies/ Cowen/ Oddo BHF
CO-Managers JMP Securities
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change